Our Thinking

Pfizer Expands โ€˜An Accord for a Healthier Worldโ€™ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries

๐—ง๐—ต๐—ถ๐—ป๐—ธ๐™๐˜ผ๐™Ž๐™. As Pfizer is currently a major topic in the media, it is worthwhile to bring attention to an especially beneficent and under-appreciated move they recently made. Pfizer expanded its global commitment to non-profit distribution of the entire gamut of pharmaceuticals and vaccines to which it has global rights to the 1.2 billion people living in 45 lower-income countries. More specifically, this move raises the number of Pfizer products covered in the Accord program from 23 to over 500. The goal? To reduce healthcare inequity worldwide.

The takeaway? More and more, we are seeing pharmaceutical companies moving away from just talking about reducing health care inequity, and moving instead toward actually doing something about it. And something really significant at that! Hopefully, those who are being hyper-critical of Pfizer and others members of our industry will take note.

You can check this story out at: https://bit.ly/3RjESUy

To view more ThinkFast posts:https://bit.ly/40j1fxK


Contact us to learn how we can help your team to make better marketing decisions based on better market research.